AVALANCHE BIOTECHNOLOGIES, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENTChange in Control and Severance Agreement • February 1st, 2016 • Avalanche Biotechnologies, Inc. • Biological products, (no disgnostic substances) • California
This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Amber Salzman (“Executive”) and Avalanche Biotechnologies, Inc. (the “Company”), effective as of the latest date set forth by the signatures of the parties hereto below (the “Effective Date”).
ACQUISITION AGREEMENT by and among AVALANCHE BIOTECHNOLOGIES, INC., ANNAPURNA THERAPEUTICS SAS, THE CONTRIBUTORS, and SHAREHOLDER REPRESENTATIVE SERVICES LLC as the CONTRIBUTORS’ REPRESENTATIVE Dated as of January 29, 2016Acquisition Agreement • February 1st, 2016 • Avalanche Biotechnologies, Inc. • Biological products, (no disgnostic substances) • Delaware
This ACQUISITION AGREEMENT (this “Agreement”), dated as of January 29, 2016, is entered into by and among Avalanche Biotechnologies, Inc., a Delaware corporation (“Parent”), Annapurna Therapeutics SAS, a French simplified joint stock company (the “Company”), each of the persons listed as shareholders of the Company on the signature pages hereof (each, a “Contributor” and together, the “Contributors”), and Shareholder Representative Services LLC, a Colorado limited liability company, acting solely in its capacity as the representative of the Contributors in connection with the transactions contemplated by this Agreement (the “Contributors’ Representative”) (hereafter, Parent, the Company and each Contributor shall sometimes be referred to as the “Parties”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
SUPPORT AND VOTING AGREEMENTSupport and Voting Agreement • February 1st, 2016 • Avalanche Biotechnologies, Inc. • Biological products, (no disgnostic substances) • Delaware
This SUPPORT AND VOTING AGREEMENT, dated as of January 29, 2016 (the “Agreement”), is entered into by and among Annapurna Therapeutics SAS, a French simplified joint stock company (the “Company”), and the undersigned, a common stockholder of Avalanche Biotechnologies, Inc., a Delaware corporation (the “Stockholder” and together with the Company, the “Parties” and each, a “Party”).
